Dabigatran-Induced Massive Spontaneous Hemothorax.

Jing Huang, Wei Lin, Dan Lv, Li Yu, Lun Wu, Haiying Jin, Zaichun Deng, Qunli Ding
{"title":"Dabigatran-Induced Massive Spontaneous Hemothorax.","authors":"Jing Huang,&nbsp;Wei Lin,&nbsp;Dan Lv,&nbsp;Li Yu,&nbsp;Lun Wu,&nbsp;Haiying Jin,&nbsp;Zaichun Deng,&nbsp;Qunli Ding","doi":"10.1007/s40800-017-0054-z","DOIUrl":null,"url":null,"abstract":"<p><p>Spontaneous hemothorax due to anticoagulant use is extremely rare in clinical practice. Dabigatran is a novel anticoagulant to prevent stroke or thromboembolic episodes in patients with nonvalvular atrial fibrillation. We report on an 83-year-old man who received dabigatran therapy (110 mg twice daily) for 7 months and developed massive spontaneous hemothorax and acute renal failure. The patient was admitted to the hospital with complaint of a dull ache in the chest and dyspnea. Chest computed tomography scan revealed massive pleural effusion in the left hemithorax with atelectasis. Acute renal failure was observed 4 days later after admission. Almost 2500 mL of blood was repeatedly drained by ultrasound-guided thoracocentesis, followed by a dramatic decrease in serum red blood cell count, hemoglobin and hematocrit. After excluding other possible causes, diagnostic withdrawal was performed for dabigatran, and plasma transfusion was conducted to supply the lost blood volume. A causal relationship was established, because the patient's renal function gradually improved and no further pleural effusion developed after dabigatran was discontinued. This is a rare case report of massive spontaneous hemothorax caused by dabigatran. Therefore, practitioners should be aware of hemothorax as a potential complication of dabigatran therapy.</p>","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40800-017-0054-z","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Safety - Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40800-017-0054-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Spontaneous hemothorax due to anticoagulant use is extremely rare in clinical practice. Dabigatran is a novel anticoagulant to prevent stroke or thromboembolic episodes in patients with nonvalvular atrial fibrillation. We report on an 83-year-old man who received dabigatran therapy (110 mg twice daily) for 7 months and developed massive spontaneous hemothorax and acute renal failure. The patient was admitted to the hospital with complaint of a dull ache in the chest and dyspnea. Chest computed tomography scan revealed massive pleural effusion in the left hemithorax with atelectasis. Acute renal failure was observed 4 days later after admission. Almost 2500 mL of blood was repeatedly drained by ultrasound-guided thoracocentesis, followed by a dramatic decrease in serum red blood cell count, hemoglobin and hematocrit. After excluding other possible causes, diagnostic withdrawal was performed for dabigatran, and plasma transfusion was conducted to supply the lost blood volume. A causal relationship was established, because the patient's renal function gradually improved and no further pleural effusion developed after dabigatran was discontinued. This is a rare case report of massive spontaneous hemothorax caused by dabigatran. Therefore, practitioners should be aware of hemothorax as a potential complication of dabigatran therapy.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
达比加群所致大量自发性血胸。
临床上由于抗凝剂的使用而引起的自发性血胸是极为罕见的。达比加群是一种新型抗凝剂,用于预防非瓣膜性房颤患者的中风或血栓栓塞发作。我们报告一例83岁男性患者接受达比加群治疗(110 mg,每日2次)7个月后出现大量自发性血胸和急性肾功能衰竭。病人因胸部隐痛和呼吸困难而住进医院。胸部电脑断层扫描显示左侧半胸大量胸腔积液并伴有肺不张。入院4天后出现急性肾功能衰竭。超声引导下胸腔穿刺反复抽取近2500 mL血液,随后血清红细胞计数、血红蛋白和红细胞压积显著下降。排除其他可能的原因后,诊断性停用达比加群,并输血浆补充丢失的血容量。由于停用达比加群后,患者肾功能逐渐改善,不再出现胸腔积液,故两者之间存在因果关系。这是一例罕见的报告大量自发性血胸由达比加群引起。因此,从业者应该意识到血胸是达比加群治疗的潜在并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acknowledgement to Referees Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital Fournier’s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1